Febuxostat

Drugs

Volumn 68, Issue 13, 2008, Pages 1865-1874

  Hair, Philip I ^a,b   McCormack, Paul L ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Febuxostat, general; Gout; Research and development

Indexed keywords

ADENURIC; ALLOPURINOL; COLCHICINE; DESIPRAMINE; FEBUXOSTAT; NAPROXEN; PLACEBO; UNCLASSIFIED DRUG; URATE; XANTHINE OXIDASE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHROPATHY; ASTHENIA; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENZYME INHIBITION; EPIGASTRIC DISCOMFORT; ERYTHEMA; FATIGUE; GASTROINTESTINAL MOTILITY DISORDER; GOUT; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERURICEMIA; LIVER FUNCTION TEST; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH DISCOMFORT; URIC ACID BLOOD LEVEL; VOMITING;

ADMINISTRATION, ORAL; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; TREATMENT OUTCOME; URIC ACID;

EID: 50249141689     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868130-00006     Document Type: Review

References (41)

1. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29 (11): 2403-6
2. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care 2005; 11 (15 Suppl.): S435-42
3. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Stat 1999; 10 (200) [online]. Available from URL: http://www.cdc.gov/ nchs/data/series/sr_10/sr10_200.pdf [Accessed 2006 Apr 18]
4. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31 (8): 1582-7
5. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005 Oct 4; 143 (7): 499-516
6. Terkeltaub RA. Gout. N Engl J Med 2003 Oct 23; 349 (17): 1647-55
7. Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drugs Aging 2007; 24 (1): 21-36
8. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64 (21): 2399-416
9. Wortmann RL, Schumacher Jr HR. Monosodium urate deposition arthropathy part II: treatment and long-term management of patients with gout. Adv Studies Med 2005; 5 (4): 183-94
10. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003 Jan 17; 278 (3): 1848-55
11. Schumacher Jr HR. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 2005 Jul; 14 (7): 893-903
12. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary gout. Ann Rheum Dis 1998 Sep; 57 (9): 545-9
13. Ipsen. Adenuric® (febuxostat) receives marketing authorisation in the European Union [media release]. 2008 May 5
14. Yamamoto T, Moriwaki Y, Fujimura Y, et al. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 2000 Jan; 60 (1): 34-40
15. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005 Mar 4; 76 (16): 1835-47
16. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993 Sep 14; 241 (2-3): 183-8
17. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol 1993 Dec 21; 250 (3): 455-60
18. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleos Nucleot Nucleic Acids 2004 Oct; 23 (8-9): 1111-6
19. Khosravan R, Kukulka MJ, Wu JT, et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. Epub 2008 Jul 17
20. Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005; 12 (1): 22-34
21. Khosravan R, Grabowski BA, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006 Jan; 46 (1): 88-102
22. Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005 Mar; 52 (3): 916-23
23. Khosravan R, Wu J-T, Lademacher C, et al. Effect of febuxostat on pharmacokinetics and pharmacodynamics of warfarin [abstract no. 71]. J Clin Pharmacol 2005 Sep; 45 (9): 1084
24. Grabowski BA, Khosravan R, Wu J-T, et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat [abstract no. 190]. Arthritis Rheum 2005 Sep; 52 (9 Suppl.): S103-4. Plus poster presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals; 2005 Nov 12-17; San Diego (CA)
25. Khosravan R, Wu J-T, Joseph-Ridge N, et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 2006 Aug; 46 (8): 855-66
26. Khosravan R, Mayer MD, Wu J-T, et al. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state [abstract no. 188]. Arthritis Rheum 2005 Sep; 52 (9 Suppl.): S102-3. Plus poster presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals; 2005 Nov 12-17; San Diego (CA)
27. Khosravan R, Erdman K, Vernillet L, et al. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects [abstract no. PI-137]. Clin Pharmacol Ther 2005 Feb; 77 (2): P43
28. Khosravan R, Grabowski B, Wu JT, et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol 2007; 65 (3): 355-63
29. Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008 May; 38 (5): 496-510
30. European Medicines Agency. Adenuric (febuxostat): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/adenuric/H-777-PI-en.pdf [Accessed 2008 Aug 1]
31. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004; 71 (6): 481-5
32. Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N Engl J Med 2005 Dec 8; 353 (23): 2450-61
33. Schumacher HR, Becker MA, Wortmann RL, et al. Febuxostat vs allopurinol and placebo in subjects with hyperuricaemia and gout: the 28-week APEX study [abstract no. 1837]. Arthritis Rheum 2005 Sep; 52 (9 Suppl.): S680
34. Becker MA, Schumacher HR, Wortmann RL, et al. The long-term clinical benefits of febuxostat vs allopurinol in subjects with gout: interim analysis of the EXCEL trial, an ongoing phase 3, open-label extension study [abstract no. FRI0483]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 431
35. Becker MA, Schumacher Jr HR, MacDonald PA, et al. Urate-lowering therapy (febuxostat or allopurinol) in subjects with gout interim results from the Febuxostat Comparative Extension Long-term Study (EXCEL) [abstract no. 757]. Arthritis Rheum 2007 Sep; 56 (9 Suppl.): S322
36. Wortmann RL, Becker MA, Schumacher Jr HR, et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial [abstract no. 1592]. Arthritis Rheum 2006 Sep; 54 (9 Suppl.): S642
37. Schumacher HR, Wortmann R, Becker M, et al. Long-term safety and efficacy of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in subjects with hyperuricemia and gout [abstract no. SAT0282]. Ann Rheum Dis 2005 Jul; 64 Suppl. 3: 498
38. Becker MA, Schumacher R, Wortmann R, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients [abstract no. 803]. Arthritis Rheum 2004 Sep; 50 (9 Suppl.): S336
39. Schumacher HR, Becker MA, Wortmann RL, et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study [abstract no. OP0130]. Ann Rheum Dis 2006 Jul; 65 Suppl. II: 93
40. Data on file. TAP Pharmaceutical Products, 2006 Mar 9
41. Prometheus Laboratories Inc. Zyloprim® (allopurinol): product information [online]. Available from URL: http://www.prometheuslabs.com/pi/ Zyloprim.pdf [Accessed 2005 Dec 8]